10:49:59 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Bokslutskommuniké 2024
2024-04-26 Kvartalsrapport 2024-Q3
2024-02-15 Kvartalsrapport 2024-Q2
2023-11-01 Ordinarie utdelning DEX 0.00 SEK
2023-10-31 Årsstämma 2024
2023-10-27 Kvartalsrapport 2024-Q1
2023-08-30 Bokslutskommuniké 2023
2023-04-28 Kvartalsrapport 2023-Q3
2023-02-15 Kvartalsrapport 2023-Q2
2022-10-31 Ordinarie utdelning DEX 0.00 SEK
2022-10-28 Årsstämma 2023
2022-10-27 Kvartalsrapport 2023-Q1
2022-08-30 Bokslutskommuniké 2022
2022-05-11 Extra Bolagsstämma 2022
2022-04-29 Kvartalsrapport 2022-Q2
2022-02-15 Kvartalsrapport 2022-Q1
2021-11-26 Ordinarie utdelning DEX 0.00 SEK
2021-11-25 Årsstämma 2022
2021-08-29 Bokslutskommuniké 2021
2021-04-29 Kvartalsrapport 2021-Q3
2021-02-02 Kvartalsrapport 2021-Q2
2020-10-22 Kvartalsrapport 2021-Q1
2020-10-09 Ordinarie utdelning DEX 0.00 SEK
2020-10-08 Årsstämma 2021
2020-08-28 Bokslutskommuniké 2020
2020-05-06 Kvartalsrapport 2020-Q3
2020-01-31 Kvartalsrapport 2020-Q2
2019-10-24 Kvartalsrapport 2020-Q1
2019-10-17 Årsstämma 2020
2019-10-11 Ordinarie utdelning DEX 0.00 SEK
2019-08-30 Bokslutskommuniké 2019
2019-05-28 Extra Bolagsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q3
2018-10-18 Kvartalsrapport 2019-Q1
2018-10-11 Ordinarie utdelning DEX 0.00 SEK
2018-10-10 Årsstämma 2019
2018-08-31 Bokslutskommuniké 2018
2018-04-25 Kvartalsrapport 2018-Q3
2018-01-29 Kvartalsrapport 2018-Q2
2017-11-10 Ordinarie utdelning DEX 0.00 SEK
2017-11-09 Årsstämma 2018
2017-10-18 Kvartalsrapport 2018-Q1
2017-08-31 Bokslutskommuniké 2017
2017-04-27 Kvartalsrapport 2017-Q3
2017-02-28 Kvartalsrapport 2017-Q2
2016-11-30 Årsstämma 2017
2016-11-30 Kvartalsrapport 2017-Q1
2016-11-04 Ordinarie utdelning DEX 0.00 SEK
2016-09-13 Extra Bolagsstämma 2016
2016-08-31 Bokslutskommuniké 2016
2016-05-26 Kvartalsrapport 2016-Q3
2016-02-25 Kvartalsrapport 2016-Q2
2015-11-27 Kvartalsrapport 2015-Q1
2015-11-26 Kvartalsrapport 2016-Q1
2015-11-04 Ordinarie utdelning DEX 0.00 SEK
2015-11-03 Årsstämma 2016
2015-08-27 Bokslutskommuniké 2015
2015-05-28 Kvartalsrapport 2015-Q3
2015-02-26 Kvartalsrapport 2015-Q2
2014-11-28 Ordinarie utdelning DEX 0.00 SEK
2014-11-27 Årsstämma 2015
2014-08-29 Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
DexTech Medical är verksamt inom bioteknik. Idag bedriver bolaget forskning och utveckling inom området för urologisk onkologi, där vanliga sjukdomar inkluderar prostatacancer. En stor del av forskningen utförs i samarbete med övriga internationella aktörer, forskningsinstitut och universitet. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget etablerades under 2004 och har sitt huvudkontor i Uppsala.
2020-06-12 11:59:15

The company's randomized Phase IIb study for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC) has now been completed with 2-year follow-up results from the last patients.

The primary endpoints of the study concerning markers of bone metabolism have been well achieved. A clear majority of patients showed reduction in their skeletal markers in the blood of the given treatment with OsteoDex. Treatment was very well tolerated  (few and mild side effects)  and good disease-slowing effect was also seen in the lowest doses. The slowing down and decline of the disease was also seen in patients who have progressed on several of the other available medications for castration-resistant prostate cancer.

The secondary endpoints of the study include overall survival studied by 24 months of post-treatment follow-up. Of the patients who responded to treatment, with deceleration or stabilization of the disease, the median survival has not yet been achieved  (> 27 months), compared with 14 months for the other patients (significance,  p <0.05). Survival 2 years after baseline is 65% for patients who responded to treatment, with deceleration or stabilization of the disease, compared with 28% for other patients (significance,  p <0.05).

The results of the study are very positive and show that OsteoDex effectively slows down the tumour disease. Overall survival data should be seen as an indication, as these data need, for natural reasons, be confirmed in a significantly larger, so-called Phase III study.

None of the modern medicines are curative in castration-resistant prostate cancer and there is therefore a great need (unmet need) for new potent and well tolerated drugs. OsteoDex has a clear potential to meet this need.

The company's intention is to sign a license agreement before the end of the current year.

"These are important results that are important in our business discussions," says CEO Anders R Holmberg."

For further information

Gösta Lundgren - CFO & Investor Relations

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on June 12, 2020.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical trial has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as treatment effect on patients who fail on existing drugs. DexTech's goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.